Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma
Explore this paper's citation graph
Summary
New clinical trial findings reported at ESMO further endorse the view that melanoma, given the continued development of novel, effective compounds, can accurately be described as the most “dynamic” field of oncology at present.
- Type
- article
- Published
- 2015-03-01
- Cited by
- 23
- References
- 12
- Access
- Open access
- OpenAlex
- https://openalex.org/W25549844
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:8179287
Keywords
Computer science
References
- Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
- 1088PDLONG-TERM SURVIVAL OF IPILIMUMAB-NAïVE PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN A PHASE 1 TRIAL.
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- 1087OEFFICACY, SAFETY, AND QUALITY OF LIFE (QOL) DATA FROM THE EORTC 18071 PHASE III TRIAL OF IPILIMUMAB (IPI) VERSUS PLACEBO AFTER COMPLETE RESECTION OF STAGE III MELANOMA.
- Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
- Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
- LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES
- Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.
- LBA4_PRCOMBI-V: A RANDOMISED, OPEN-LABEL, PHASE III STUDY COMPARING THE COMBINATION OF DABRAFENIB (D) AND TRAMETINIB (T) WITH VEMURAFENIB (V) AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH UNRESECTABLE OR METASTATIC BRAF V600E/K MUTATION-POSITIVE CUTANEOUS MELANOMA
- LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY
Cited by
- Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy
- Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy
- Lineage reprogramming of tumor-infiltrating cytotoxic T lymphocytes using protein stem cell transcription factors
- Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer
- Effects of a novel Nodal-targeting monoclonal antibody in melanoma
- Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application
- Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer
- Cancer-Targeted Nanotheranostics: Recent Advances and Perspectives.
- Nanomedicine for Cancer Immunotherapy: Tracking Cancer-Specific T-Cells in Vivo with Gold Nanoparticles and CT Imaging.
- Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
- Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells
- Immunological effect of local ablation combined with immunotherapy on solid malignancies
- Current status and future direction in the management of malignant melanoma
- Electrochemotherapy with anti-PD-1 treatment induced durable complete response in heavily pretreated metastatic melanoma patient.
- Optogenetic regulation of transcription
- Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression
- Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer
- Prognostic analysis of tumor mutation burden combined with immune infiltration of Thymic epithelial tumors
- A structural perspective on the design of decoy immune modulators.
- Research progress on anti-tumor immune effect of cryoablation
Related papers
No related papers recorded.